DOCSLIB.ORG

Identification and Interaction Analysis of Molecular Markers in Pancreatic

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text

Load more

medRxiv preprint doi: https://doi.org/10.1101/2020.12.20.20248601; this version posted December 23, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission. Identification and Interaction Analysis of Molecular Markers in Pancreatic Ductal Adenocarcinoma by Integrated Bioinformatics Analysis and Molecular Docking Experiments Basavaraj Vastrad1 , Chanabasayya Vastrad *2, Anandkumar Tengli3 1. Department of Biochemistry, Basaveshwar College of Pharmacy, Gadag, Karnataka 582103, India. 2. Biostatistics and Bioinformatics,Chanabasava Nilaya, Bharthinagar, Dharwad, Karanataka 580001, India. 3. Department of Pharmaceutical Chemistry, JSS College of Pharmacy, Mysuru and JSS Academy of Higher Education & Research, Mysuru- 570015, Karnataka, India. * Chanabasayya Vastrad [email protected] Ph: +919480073398 Chanabasava Nilaya, Bharthinagar, Dharwad 580001 , Karanataka, India NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice. medRxiv preprint doi: https://doi.org/10.1101/2020.12.20.20248601; this version posted December 23, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission. Abstract The current investigation aimed to mine therapeutic molecular targets that play an key part in the advancement of pancreatic ductal adenocarcinoma (PDAC). The expression profiling by high throughput sequencing dataset profile GSE133684 dataset was downloaded from the Gene Expression Omnibus (GEO) database. Limma package of R was used to identify differentially expressed genes (DEGs). Functional enrichment analysis of DEGs were performed. Protein-protein interaction (PPI) networks of the DEGs were constructed. An integrated gene regulatory network was built including DEGs, microRNAs (miRNAs), and transcription factors. Furthermore, consistent hub genes were further validated. Molecular docking experiment was conducted. A total of 463 DEGs (232 up regulated and 231 down regulated genes) were identified between very early PDAC and normal control samples. The results of Functional enrichment analysis revealed that the DEGs were significantly enriched in vesicle organization, secretory vesicle, protein dimerization activity, lymphocyte activation, cell surface, transferase activity, transferring phosphorus-containing groups, hemostasis and adaptive immune system. The PPI network and gene regulatory network of up regulated genes and down regulated genes were established, and hub genes were identified. The expression of hub genes (CCNB1, FHL2, HLA-DPA1 and TUBB1) were also validated to be differentially expressed among PDAC and normal control samples. Molecular docking experiment predicted the novel inhibitory molecules for CCNB1 and FHL2. The identification of hub genes in PDAC enhances our understanding of the molecular mechanisms underlying the progression of this disease. These genes may be potential diagnostic biomarkers and/or therapeutic molecular targets in patients with PDAC. Keywords: pancreatic ductal adenocarcinoma; bioinformatics analysis; biomarker; enrichment analysis; differentially expressed genes medRxiv preprint doi: https://doi.org/10.1101/2020.12.20.20248601; this version posted December 23, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission. Introduction Pancreatic ductal adenocarcinoma (PDAC) is one of the most prevalent cancers in the world and primary tumor of the pancreas [1]. PDAC is a global burden ranking 15th in terms of incidence and fourth in terms of mortality [2]. Despite new developments in multimodal therapy its overall 5-year survival rate remains less than 8% [3]. PDAC treatment commonly includes surgery, radiation, chemotherapy and immunotherapy [4]. However, PDAC remains common and malignant due to recurrence and metastasis, and ultimately key cause of PDAC associated death [5]. Therefore, there is a vital need to advance new diagnostic strategies and therapeutic agents to upgrade the prognosis of patients with PDAC. The molecular mechanisms of PDAC tumorigenesis and development remain imprecise. It is therefore key to identify novel genes and pathways that are linked with PDAC tumorigenesis and patient prognosis, which may not only help to illuminate the underlying molecular mechanisms involved, but also to disclose novel diagnostic markers and therapeutic targets. Oji et al [6] demonstrated that the over expression of WT1 is linked with prognosis in patients with PDAC. A previous investigation reported that phosphoinositide 3-kinase signaling pathway is linked with development of PDAC [7]. Expression profiling by high throughput sequencing can promptly uncover gene expression on a global basis and are specially useful in identifying for differentially expressed genes (DEGs) [8]. A huge amount of data has been generated through the use of microarrays and the majority of such data has been deposited and saved in public databases. Previous investigations concerning PDAC gene expression profiling have diagnosed hundreds of DEGs [9]. The aim of this investigation was to identify hub genes and pathways in PDAC using bioinformatics methods. Our investigation contributes predictable biomarkers for early detection and prognosis, as well as effective drug targets for treating PDAC. Materials and methods Sequencing data medRxiv preprint doi: https://doi.org/10.1101/2020.12.20.20248601; this version posted December 23, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission. PDAC expression profiling by high throughput sequencing dataset in this investigation was downloaded from the GEO database (https://www.ncbi.nlm.nih.gov/gds/) [10]. The DEGs were considered by 1 independent PDAC dataset, GSE133684 [11] with 284 PDAC and 117 normal samples. The GSE133684 expression profiling by high throughput sequencing data was based on the GPL20795 HiSeq X Ten (Homo sapiens) platform.. Identification of DEGs The Limma package of R language were used to normalize and convert the raw data to expression profiles [12]. The limma package of R language was used for DEGs between PDAC and normal control samples [12]. The P-value was adjusted by the Benjamini-Hochberg method [13]. An adjusted P-value <0.05 and |log2 fold change (FC) | >1 were considered as threshold values for DEGs identification. The ggplot2 package and gplots package of R language was used to generate volcano plot and heat map. The identified DEGs were preserved for further bioinformatics analysis. GO analysis and pathway enrichment analysis of DEGs The GO repository (http://geneontology.org/) [14] consists of a massive set of annotation terms and is generally used for annotating genes and identifying the distinctive biological aspects for expression profiling by high throughput sequencing data. The REACTOME database (https://reactome.org/) [15] contains data on known genes and their biochemical functions and is used for identifying functional and metabolic pathways. By performing the GO and REACTOME enrichment analysis at the functional level, we can boost a better understanding of the roles of these DEGs in the induction and in the advancement of PDAC. The ToppGene (ToppFun) (https://toppgene.cchmc.org/enrichment.jsp) [16] is an online resource that add tools for functional annotation and bioinformatics analysis. Both GO categories and REACTOME pathway enrichment analysis were implemented using ToppGene to inform the functions of these DEGs. P<0.05 was considered to indicate a statistically significant difference. Protein-protein interaction (PPI) network construction and module analysis medRxiv preprint doi: https://doi.org/10.1101/2020.12.20.20248601; this version posted December 23, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission. The online database IID interactome (http://iid.ophid.utoronto.ca//) [17] was used to construct a PPI network of the proteins encoded by DEGs. Then, Cytoscape software (Version 3.8.1) [18] was applied to perform protein interaction association network analysis and analyze the interaction correlation of the candidate proteins encoded by the DEGs in PDAC. Next, the Network Analyzer Cytoscape plug-in was applied to calculate node degree [19], betweenness centrality [20], stress centrality [21], closeness centrality [22]. Finally, the PEWCC1 (http://apps.cytoscape.org/apps/PEWCC1) [23] module for Cytoscape was used to collect the significant modules in the PPI network complex. Construction of miRNA-DEG regulatory network The miRNet database (https://www.mirnet.ca/) [24] is a database, containing miRNAs involved in various diseases. The miRNAs related to PDAC were searched from miRNet database. Through getting the intersection of the miRNAs and the DEGs,
Recommended publications
  • Detection of Interacting Transcription Factors in Human Tissues Using

    Detection of Interacting Transcription Factors in Human Tissues Using

    Myšičková and Vingron BMC Genomics 2012, 13(Suppl 1):S2 http://www.biomedcentral.com/1471-2164/13/S1/S2 PROCEEDINGS Open Access Detection of interacting transcription factors in human tissues using predicted DNA binding affinity Alena Myšičková*, Martin Vingron From The Tenth Asia Pacific Bioinformatics Conference (APBC 2012) Melbourne, Australia. 17-19 January 2012 Abstract Background: Tissue-specific gene expression is generally regulated by combinatorial interactions among transcription factors (TFs) which bind to the DNA. Despite this known fact, previous discoveries of the mechanism that controls gene expression usually consider only a single TF. Results: We provide a prediction of interacting TFs in 22 human tissues based on their DNA-binding affinity in promoter regions. We analyze all possible pairs of 130 vertebrate TFs from the JASPAR database. First, all human promoter regions are scanned for single TF-DNA binding affinities with TRAP and for each TF a ranked list of all promoters ordered by the binding affinity is created. We then study the similarity of the ranked lists and detect candidates for TF-TF interaction by applying a partial independence test for multiway contingency tables. Our candidates are validated by both known protein-protein interactions (PPIs) and known gene regulation mechanisms in the selected tissue. We find that the known PPIs are significantly enriched in the groups of our predicted TF-TF interactions (2 and 7 times more common than expected by chance). In addition, the predicted interacting TFs for studied tissues (liver, muscle, hematopoietic stem cell) are supported in literature to be active regulators or to be expressed in the corresponding tissue.
  • And MMP-Mediated Cell–Matrix Interactions in the Tumor Microenvironment

    And MMP-Mediated Cell–Matrix Interactions in the Tumor Microenvironment

    International Journal of Molecular Sciences Review Hold on or Cut? Integrin- and MMP-Mediated Cell–Matrix Interactions in the Tumor Microenvironment Stephan Niland and Johannes A. Eble * Institute of Physiological Chemistry and Pathobiochemistry, University of Münster, 48149 Münster, Germany; [email protected] * Correspondence: [email protected] Abstract: The tumor microenvironment (TME) has become the focus of interest in cancer research and treatment. It includes the extracellular matrix (ECM) and ECM-modifying enzymes that are secreted by cancer and neighboring cells. The ECM serves both to anchor the tumor cells embedded in it and as a means of communication between the various cellular and non-cellular components of the TME. The cells of the TME modify their surrounding cancer-characteristic ECM. This in turn provides feedback to them via cellular receptors, thereby regulating, together with cytokines and exosomes, differentiation processes as well as tumor progression and spread. Matrix remodeling is accomplished by altering the repertoire of ECM components and by biophysical changes in stiffness and tension caused by ECM-crosslinking and ECM-degrading enzymes, in particular matrix metalloproteinases (MMPs). These can degrade ECM barriers or, by partial proteolysis, release soluble ECM fragments called matrikines, which influence cells inside and outside the TME. This review examines the changes in the ECM of the TME and the interaction between cells and the ECM, with a particular focus on MMPs. Keywords: tumor microenvironment; extracellular matrix; integrins; matrix metalloproteinases; matrikines Citation: Niland, S.; Eble, J.A. Hold on or Cut? Integrin- and MMP-Mediated Cell–Matrix 1. Introduction Interactions in the Tumor Microenvironment.
  • Human ADAM12 Quantikine ELISA

    Human ADAM12 Quantikine ELISA

    Quantikine® ELISA Human ADAM12 Immunoassay Catalog Number DAD120 For the quantitative determination of A Disintegrin And Metalloproteinase domain- containing protein 12 (ADAM12) concentrations in cell culture supernates, serum, plasma, and urine. This package insert must be read in its entirety before using this product. For research use only. Not for use in diagnostic procedures. TABLE OF CONTENTS SECTION PAGE INTRODUCTION .....................................................................................................................................................................1 PRINCIPLE OF THE ASSAY ...................................................................................................................................................2 LIMITATIONS OF THE PROCEDURE .................................................................................................................................2 TECHNICAL HINTS .................................................................................................................................................................2 MATERIALS PROVIDED & STORAGE CONDITIONS ...................................................................................................3 OTHER SUPPLIES REQUIRED .............................................................................................................................................3 PRECAUTIONS .........................................................................................................................................................................4
  • Propranolol-Mediated Attenuation of MMP-9 Excretion in Infants with Hemangiomas

    Propranolol-Mediated Attenuation of MMP-9 Excretion in Infants with Hemangiomas

    Supplementary Online Content Thaivalappil S, Bauman N, Saieg A, Movius E, Brown KJ, Preciado D. Propranolol-mediated attenuation of MMP-9 excretion in infants with hemangiomas. JAMA Otolaryngol Head Neck Surg. doi:10.1001/jamaoto.2013.4773 eTable. List of All of the Proteins Identified by Proteomics This supplementary material has been provided by the authors to give readers additional information about their work. © 2013 American Medical Association. All rights reserved. Downloaded From: https://jamanetwork.com/ on 10/01/2021 eTable. List of All of the Proteins Identified by Proteomics Protein Name Prop 12 mo/4 Pred 12 mo/4 Δ Prop to Pred mo mo Myeloperoxidase OS=Homo sapiens GN=MPO 26.00 143.00 ‐117.00 Lactotransferrin OS=Homo sapiens GN=LTF 114.00 205.50 ‐91.50 Matrix metalloproteinase‐9 OS=Homo sapiens GN=MMP9 5.00 36.00 ‐31.00 Neutrophil elastase OS=Homo sapiens GN=ELANE 24.00 48.00 ‐24.00 Bleomycin hydrolase OS=Homo sapiens GN=BLMH 3.00 25.00 ‐22.00 CAP7_HUMAN Azurocidin OS=Homo sapiens GN=AZU1 PE=1 SV=3 4.00 26.00 ‐22.00 S10A8_HUMAN Protein S100‐A8 OS=Homo sapiens GN=S100A8 PE=1 14.67 30.50 ‐15.83 SV=1 IL1F9_HUMAN Interleukin‐1 family member 9 OS=Homo sapiens 1.00 15.00 ‐14.00 GN=IL1F9 PE=1 SV=1 MUC5B_HUMAN Mucin‐5B OS=Homo sapiens GN=MUC5B PE=1 SV=3 2.00 14.00 ‐12.00 MUC4_HUMAN Mucin‐4 OS=Homo sapiens GN=MUC4 PE=1 SV=3 1.00 12.00 ‐11.00 HRG_HUMAN Histidine‐rich glycoprotein OS=Homo sapiens GN=HRG 1.00 12.00 ‐11.00 PE=1 SV=1 TKT_HUMAN Transketolase OS=Homo sapiens GN=TKT PE=1 SV=3 17.00 28.00 ‐11.00 CATG_HUMAN Cathepsin G OS=Homo
  • Quantikine® ELISA

    Quantikine® ELISA

    Quantikine® ELISA Human ADAMTS13 Immunoassay Catalog Number DADT130 For the quantitative determination of human A Disintegrin And Metalloproteinase with Thombospondin type 1 motif, 13 (ADAMTS13) concentrations in cell culture supernates, serum, and plasma. This package insert must be read in its entirety before using this product. For research use only. Not for use in diagnostic procedures. TABLE OF CONTENTS SECTION PAGE INTRODUCTION .....................................................................................................................................................................1 PRINCIPLE OF THE ASSAY ...................................................................................................................................................2 LIMITATIONS OF THE PROCEDURE .................................................................................................................................2 TECHNICAL HINTS .................................................................................................................................................................2 MATERIALS PROVIDED & STORAGE CONDITIONS ...................................................................................................3 OTHER SUPPLIES REQUIRED .............................................................................................................................................4 PRECAUTIONS .........................................................................................................................................................................4
  • Crystal Structures of the Noncatalytic Domains of ADAMTS13 Reveal Multiple Discontinuous Exosites for Von Willebrand Factor

    Crystal Structures of the Noncatalytic Domains of ADAMTS13 Reveal Multiple Discontinuous Exosites for Von Willebrand Factor

    Crystal structures of the noncatalytic domains of ADAMTS13 reveal multiple discontinuous exosites for von Willebrand factor Masashi Akiyamaa,1, Soichi Takedaa,1,2, Koichi Kokamea, Junichi Takagib, and Toshiyuki Miyataa,2 aNational Cardiovascular Center Research Institute, Suita, Osaka 565-8565, Japan; and bLaboratory of Protein Synthesis and Expression, Institute for Protein Research, Osaka University, Suita, Osaka 565-0871, Japan Edited by Philip W. Majerus, Washington University Medical School, St. Louis, MO, and approved September 16, 2009 (received for review August 27, 2009) ADAMTS13 specifically cleaves plasma von Willebrand factor (VWF) distribution of VWF multimers is important for normal hemo- and thereby controls VWF-mediated platelet thrombus formation. stasis, as large multimers are hemostatically more active than Severe deficiencies in ADAMTS13 can cause life-threatening throm- small multimers (3). Deficiencies in ADAMTS13 activity, caused botic thrombocytopenic purpura. Here, we determined 2 crystal either by genetic mutations in the ADAMTS13 gene or by structures of ADAMTS13-DTCS (residues 287–685), an exosite- acquired inhibitory autoantibodies directed against the AD- containing human ADAMTS13 fragment, at 2.6-Å and 2.8-Å reso- AMTS13 protein, results in the accumulation of UL-VWF in the lution. The structures revealed folding similarities between the plasma (8–11). The UL-VWF accumulation leads to the forma- disintegrin-like (D) domain and the N-terminal portion of the tion of disseminated platelet-rich microthrombi in the micro- cysteine-rich domain (designated the CA domain). The spacer (S) vasculature, which results in the life-threatening disease, throm- domain forms a globular functional unit with a 10-stranded botic thrombocytopenic purpura (TTP).
  • The Inhibitory NKR-P1B:Clr-B Recognition Axis Facilitates Detection of Oncogenic Transformation and Cancer Immunosurveillance Miho Tanaka1,2, Jason H

    The Inhibitory NKR-P1B:Clr-B Recognition Axis Facilitates Detection of Oncogenic Transformation and Cancer Immunosurveillance Miho Tanaka1,2, Jason H

    Published OnlineFirst April 24, 2018; DOI: 10.1158/0008-5472.CAN-17-1688 Cancer Tumor Biology and Immunology Research The Inhibitory NKR-P1B:Clr-b Recognition Axis Facilitates Detection of Oncogenic Transformation and Cancer Immunosurveillance Miho Tanaka1,2, Jason H. Fine1,2, Christina L. Kirkham1,2, Oscar A. Aguilar1,2, Antoaneta Belcheva1, Alberto Martin1, Troy Ketela3,4, Jason Moffat3,4, David S.J. Allan1,2, and James R. Carlyle1,2 Abstract Natural killer (NK) cells express receptors specific for MHC class in a primary lymphoma model despite preferential rejection of – – I (MHC-I) molecules involved in "missing-self" recognition of Clr-b / hematopoietic cells previously observed following adop- cancer and virus-infected cells. Here we elucidate the role of MHC- tive transfer into na€ve wild-type mice in vivo. Collectively, these I-independent NKR-P1B:Clr-b interactions in the detection of findings suggest that the inhibitory NKR-P1B:Clr-b axis plays a oncogenic transformation by NK cells. Ras oncogene overexpres- beneficial role in innate detection of oncogenic transformation sion was found to promote a real-time loss of Clr-b on mouse via NK-cell–mediated cancer immune surveillance, in addition fibroblasts and leukemia cells, mediated in part via the Raf/MEK/ to a pathologic role in the immune escape of primary lympho- ERK and PI3K pathways. Ras-driven Clr-b downregulation ma cells in Em-cMyc mice in vivo. These results provide a model occurred at the level of the Clrb (Clec2d) promoter, nascent Clr-b for the human NKR-P1A:LLT1 system in cancer immunosur- transcripts, and cell surface Clr-b protein, in turn promoting veillance in patients with lymphoma and suggest it may rep- missing-self recognition via the NKR-P1B inhibitory receptor.
  • A Computational Approach for Defining a Signature of Β-Cell Golgi Stress in Diabetes Mellitus

    A Computational Approach for Defining a Signature of Β-Cell Golgi Stress in Diabetes Mellitus

    Page 1 of 781 Diabetes A Computational Approach for Defining a Signature of β-Cell Golgi Stress in Diabetes Mellitus Robert N. Bone1,6,7, Olufunmilola Oyebamiji2, Sayali Talware2, Sharmila Selvaraj2, Preethi Krishnan3,6, Farooq Syed1,6,7, Huanmei Wu2, Carmella Evans-Molina 1,3,4,5,6,7,8* Departments of 1Pediatrics, 3Medicine, 4Anatomy, Cell Biology & Physiology, 5Biochemistry & Molecular Biology, the 6Center for Diabetes & Metabolic Diseases, and the 7Herman B. Wells Center for Pediatric Research, Indiana University School of Medicine, Indianapolis, IN 46202; 2Department of BioHealth Informatics, Indiana University-Purdue University Indianapolis, Indianapolis, IN, 46202; 8Roudebush VA Medical Center, Indianapolis, IN 46202. *Corresponding Author(s): Carmella Evans-Molina, MD, PhD ([email protected]) Indiana University School of Medicine, 635 Barnhill Drive, MS 2031A, Indianapolis, IN 46202, Telephone: (317) 274-4145, Fax (317) 274-4107 Running Title: Golgi Stress Response in Diabetes Word Count: 4358 Number of Figures: 6 Keywords: Golgi apparatus stress, Islets, β cell, Type 1 diabetes, Type 2 diabetes 1 Diabetes Publish Ahead of Print, published online August 20, 2020 Diabetes Page 2 of 781 ABSTRACT The Golgi apparatus (GA) is an important site of insulin processing and granule maturation, but whether GA organelle dysfunction and GA stress are present in the diabetic β-cell has not been tested. We utilized an informatics-based approach to develop a transcriptional signature of β-cell GA stress using existing RNA sequencing and microarray datasets generated using human islets from donors with diabetes and islets where type 1(T1D) and type 2 diabetes (T2D) had been modeled ex vivo. To narrow our results to GA-specific genes, we applied a filter set of 1,030 genes accepted as GA associated.
  • Remote Ischemic Preconditioning (RIPC) Modifies Plasma Proteome in Humans

    Remote Ischemic Preconditioning (RIPC) Modifies Plasma Proteome in Humans

    Remote Ischemic Preconditioning (RIPC) Modifies Plasma Proteome in Humans Michele Hepponstall1,2,3,4, Vera Ignjatovic1,3, Steve Binos4, Paul Monagle1,3, Bryn Jones1,2, Michael H. H. Cheung1,2,3, Yves d’Udekem1,2, Igor E. Konstantinov1,2,3* 1 Haematology Research, Murdoch Childrens Research Institute; Melbourne, Victoria, Australia, 2 Cardiac Surgery Unit and Cardiology, Royal Children’s Hospital; Melbourne, Victoria, Australia, 3 Department of Paediatrics, The University of Melbourne; Melbourne, Victoria, Australia, 4 Bioscience Research Division, Department of Primary Industries, Melbourne, Victoria, Australia Abstract Remote Ischemic Preconditioning (RIPC) induced by brief episodes of ischemia of the limb protects against multi-organ damage by ischemia-reperfusion (IR). Although it has been demonstrated that RIPC affects gene expression, the proteomic response to RIPC has not been determined. This study aimed to examine RIPC induced changes in the plasma proteome. Five healthy adult volunteers had 4 cycles of 5 min ischemia alternating with 5 min reperfusion of the forearm. Blood samples were taken from the ipsilateral arm prior to first ischaemia, immediately after each episode of ischemia as well as, at 15 min and 24 h after the last episode of ischemia. Plasma samples from five individuals were analysed using two complementary techniques. Individual samples were analysed using 2Dimensional Difference in gel electrophoresis (2D DIGE) and mass spectrometry (MS). Pooled samples for each of the time-points underwent trypsin digestion and peptides generated were analysed in triplicate using Liquid Chromatography and MS (LC-MS). Six proteins changed in response to RIPC using 2D DIGE analysis, while 48 proteins were found to be differentially regulated using LC-MS.
  • Inhibition of Tumor Growth by Antibody to ADAMTS1 in Mouse Xenografts of Breast Cancer

    Inhibition of Tumor Growth by Antibody to ADAMTS1 in Mouse Xenografts of Breast Cancer

    ANTICANCER RESEARCH 31: 3839-3842 (2011) Inhibition of Tumor Growth by Antibody to ADAMTS1 in Mouse Xenografts of Breast Cancer TOMOHIRO HIRANO1, KUNITAKA HIROSE2, KENICHI SAKURAI1, MAKOTO MAKISHIMA3, KENJI SASAKI4† and SADAO AMANO1 1Division of Breast and Endocrine Surgery, Department of Surgery, 3Division of Biochemistry, Department of Biomedical Sciences and 4Division of Plastic and Reconstructive Surgery, Department of Plastic and Reconstructive Surgery, Nihon University School of Medicine, Itabashi-ku, Tokyo, Japan; 2Biomedical Research Laboratory, Kureha Chemical Industry Co., Ltd., Shinjuku-ku, Tokyo, Japan Abstract. Background: A disintegrin and metalloproteinase carcinoma and Lewis lung carcinoma cells (4). ADAMTS1 and with thrombospondin motifs-1 (ADAMTS1), a member of the matrix metalloproteinase-1 synergistically promote bone ADAMTS family of proteases, is involved in the shedding of metastasis of breast cancer cells by shedding epidermal growth epidermal growth factor (EGF)-like ligands such as factor (EGF)-like ligands, including heparin-binding EGF (HB- amphiregulin, which activate the EGF receptor. Since EGF), amphiregulin, and transforming growth factor α, from ADAMTS1 has been implicated in aggressive breast tumor cells, and subsequent activation of the EGF receptor carcinogenesis, we examined potential antitumor effects of (EGFR) (5). In human breast samples, ADAMTS1 mRNA is antibody to ADAMTS1 in a mouse model of breast cancer. expressed in non-neoplastic mammary tissues, predominantly in Materials and Methods: BALB/c female mice were inoculated stromal fibroblasts, and is significantly down-regulated in breast with syngenic 4T1 breast cancer cells and treated with anti- carcinomas (6). The erythroblastic leukemia viral oncogene ADAMTS1 antibody or control IgG. Tumor volume and weight homolog (ERBB) family of receptor tyrosine kinases, were evaluated.
  • Tolerance to Sustained Activation of the Camp/Creb Pathway Activity in Osteoblastic Cells Is Enabled by Loss of P53 Mannu K

    Tolerance to Sustained Activation of the Camp/Creb Pathway Activity in Osteoblastic Cells Is Enabled by Loss of P53 Mannu K

    Walia et al. Cell Death and Disease (2018) 9:844 DOI 10.1038/s41419-018-0944-8 Cell Death & Disease ARTICLE Open Access Tolerance to sustained activation of the cAMP/Creb pathway activity in osteoblastic cells is enabled by loss of p53 Mannu K. Walia1, Scott Taylor1,PatriciaW.M.Ho1,T.JohnMartin1,2 and Carl R. Walkley 1,2,3 Abstract The loss of p53 function is a central event in the genesis of osteosarcoma (OS). How mutation of p53 enables OS development from osteoblastic lineage cells is poorly understood. We and others have reported a key role for elevated and persistent activation of the cAMP/PKA/Creb1 pathway in maintenance of OS. In view of the osteoblast lineage being the cell of origin of OS, we sought to determine how these pathways interact within the context of the normal osteoblast. Normal osteoblasts (p53 WT) rapidly underwent apoptosis in response to acute elevation of cAMP levels or activity, whereas p53-deficient osteoblasts tolerated this aberrant cAMP/Creb level and activity. Using the p53 activating small-molecule Nutlin-3a and cAMP/Creb1 activator forskolin, we addressed the question of how p53 responds to the activation of cAMP. We observed that p53 acts dominantly to protect cells from excessive cAMP accumulation. We identify a Creb1-Cbp complex that functions together with and interacts with p53. Finally, translating these results we find that a selective small-molecule inhibitor of the Creb1-Cbp interaction demonstrates selective toxicity to OS cells where this pathway is constitutively active. This highlights the cAMP/Creb axis as a potentially actionable therapeutic vulnerability in p53-deficient tumors such as OS.
  • Non-Canonical Activation of CREB Mediates Neuroprotection in a C

    Non-Canonical Activation of CREB Mediates Neuroprotection in a C

    bioRxiv preprint doi: https://doi.org/10.1101/261420; this version posted February 7, 2018. The copyright holder for this preprint (which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission. Non-Canonical Activation of CREB Mediates Neuroprotection in a C. elegans Model of Excitotoxic Necrosis K. Genevieve Feldmann1,2, Ayesha Chowdhury1,2, Jessi Becker3, N’Gina McAlpin3, Taqwa Ahmed4, Syed Haider3, Jian X. Richard Xia4, Karina Diaz4, Monal G. Mehta5, and Itzhak Mano1,2,4,CA 1 Department of Molecular, Cellular and Biomedical Sciences, CDI Cluster on Neural Development and Repair, The CUNY School of Medicine, City College (CCNY), The City University of New York (CUNY) 2 The CUNY Neuroscience Collaborative PhD Program, CUNY Graduate Center 3 Undergraduate Program in Biology, CCNY, CUNY 4 The Sophie Davis BS/MD program, CUNY School of Medicine 5 Robert Wood Johnson Medical School, Rutgers – The State University of New Jersey CA Corresponding Author: Itzhak Mano, Ph.D. Department of Molecular, Cellular and Biomedical Sciences Center for Discovery & Innovation, Cluster on Neural Development and Repair The CUNY School of Medicine at City College & The CUNY Graduate Center The City University of New York CDI building room 3-382 85 St. Nicholas Terrace, New York, NY 10031 E-mail: [email protected] Office Phone:(212) 6507965 Lab Phone:(212) 6505334 www.manolab.org Running Title: Non-canonical CREB activation in nematode excitotoxicity 1 bioRxiv preprint doi: https://doi.org/10.1101/261420; this version posted February 7, 2018. The copyright holder for this preprint (which was not certified by peer review) is the author/funder.